Brainsway Ltd. Sponsored ADR (BWAY) – What Are Researchers Saying About This Stock?

Shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $18.20.

Several research analysts have issued reports on BWAY shares. Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a research note on Sunday, August 2nd. New Street Research reaffirmed a “buy” rating on shares of Brainsway in a research note on Friday, July 24th. Weiss Ratings cut shares of Brainsway from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. HC Wainwright reissued a “buy” rating on shares of Brainsway in a research report on Friday. Finally, LADENBURG THALM/SH SH upped their target price on Brainsway from $18.00 to $18.80 and gave the company a “buy” rating in a research report on Thursday, August 13th.

Institutional Investors Weigh In On Brainsway

A number of hedge funds have recently made changes to their positions in BWAY. HWG Holdings LP purchased a new stake in Brainsway in the 3rd quarter worth approximately $3,340,000. Tidal Investments LLC increased its holdings in Brainsway by 492.8% during the second quarter. Tidal Investments LLC now owns 89,248 shares of the company’s stock worth $1,384,000 after buying an additional 74,193 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in Brainsway by 434.6% in the 2nd quarter. NewEdge Advisors LLC now owns 18,830 shares of the company’s stock valued at $292,000 after purchasing an additional 15,308 shares during the period. Ballast Advisors LLC bought a new stake in shares of Brainsway during the first quarter worth $55,000. Finally, Bank of America Corp DE acquired a new stake in Brainsway during the first quarter worth approximately $206,000. Institutional investors own 30.11% of the company’s stock.

Brainsway Stock Performance

Shares of BWAY opened at $11.36 on Wednesday. Brainsway has a 1-year low of $7.14 and a 1-year high of $17.40. The firm has a market cap of $457.24 million, a PE ratio of 25.82 and a beta of 1.36. The firm has a fifty day simple moving average of $12.95 and a two-hundred day simple moving average of $13.93.

Brainsway (NASDAQ:BWAY) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.04. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. The company had revenue of $17.11 million during the quarter, compared to analysts’ expectations of $16.54 million. As a group, research analysts forecast that Brainsway will post 0.33 EPS for the current fiscal year.

About Brainsway

BrainsWay Ltd. (NASDAQ: BWAY) is a medical technology company that develops and commercializes noninvasive therapies for brain disorders. Its core technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses a helmet-like device to deliver magnetic stimulation to targeted areas of the brain.

The company’s Deep TMS systems are used in the treatment of major depressive disorder and obsessive-compulsive disorder, and have also received regulatory clearances for certain additional indications, including smoking cessation.